HR 5850 · 118th Congress
To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.
This bill hasn't been enriched yet — fetch cosponsors, actions, subjects, titles, and summaries from Congress.gov.
Latest action
2023-10-06 — Referred to the Subcommittee on Health.
Sponsor
Tracey MannCosponsors
Cosponsors not yet fetched. Run
concord scrape bills enrich --bill-ids 118-hr-5850
to populate.
Action history
Action history not yet fetched. Run
concord scrape bills enrich --bill-ids 118-hr-5850
to populate.
Subjects
Subjects not yet fetched. Run
concord scrape bills enrich --bill-ids 118-hr-5850
to populate.
Titles
Titles not yet fetched. Run
concord scrape bills enrich --bill-ids 118-hr-5850
to populate.
Summaries
Summaries not yet fetched. Run
concord scrape bills enrich --bill-ids 118-hr-5850
to populate.
Vote history
No votes recorded for this bill yet.
Coming in later phases
Committee path (Phase 4)
Committee referrals and reports will appear here.
Search within this bill (Phase 5)
Bill text will become searchable here.